Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 76
- Registration Number
- NCT01565694
- Locations
- 🇩🇰
Site DK4501, Aarhus, Denmark
🇭🇺Site HU3602, Miskolc, Hungary
🇲🇽Site MX5203, Leon, Mexico
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 138
- Registration Number
- NCT01559389
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Soonchunhyang University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01533597
- Locations
- 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 6
- Registration Number
- NCT01530373
- Locations
- 🇺🇸
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Jeong Gu Lee
- Target Recruit Count
- 311
- Registration Number
- NCT01505439
- Locations
- 🇰🇷
Site KR00005, Pusan, Korea, Republic of
🇰🇷SIte KR00004, Incheon, Korea, Republic of
🇰🇷Site KR00006, Seoul, Korea, Republic of
Post Marketing Survey of Vesicare in Japan
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1160
- Registration Number
- NCT01489709
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Michael E. Chua
- Target Recruit Count
- 94
- Registration Number
- NCT01486706
- Locations
- 🇵🇭
Comprehensive Pelvic Floor Center- St. Luke's Medical Center, Quezon City, National Capital Region, Philippines
The Effect of Solifenacin on Post Void Dribbling in Women
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 118
- Registration Number
- NCT01470001
- Locations
- 🇺🇸
UW Hospital and Clinics, Madison, Wisconsin, United States
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Timothy Boone, MD, PhD
- Target Recruit Count
- 10
- Registration Number
- NCT01457573
- Locations
- 🇺🇸
The Methodist Hospital System, Houston, Texas, United States
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2011-08-26
- Lead Sponsor
- Adana Numune Training and Research Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT01423838
- Locations
- 🇹🇷
Turkish Republic Ministry of Health Adana Numune Training and Research Hospital, Adana, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.